
    
      Subjects will enter the trial after maintaining 4 days of abstinence. During this period
      multiple assessments will be collected. After entering the double blind treatment portion of
      the study, they will be evaluated weekly for the first month, then bi-weekly until week 12
      and again at week 16. There will be two follow-up visits at weeks 28 and 40. Urinary
      riboflavin and pill counts will be utilized to determine compliance with the medication
      regime.

      Comparison(s): Naltrexone (50 mg/day) alone for 16-weeks; naltrexone (50 mg/day) for 16-weeks
      plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks, or inactive
      placebos. All subjects will receive up to 20 sessions of individual alcohol counseling.
    
  